GHK-Cu and Hair Growth: What Studies Show

Reviewed by Thomas Okafor, Peptide Chemist · Last reviewed October 17, 2026

GHK-Cu hair growth claims are everywhere: serums, clinic pages and social posts describe the copper peptide as a reliable follicle booster, sometimes “as effective as minoxidil.” The published research is much smaller than that, and some of the most-repeated studies didn’t test GHK-Cu at all. We traced the main hair studies back to their original papers. What we found is a handful of lab, animal and small human studies, several of them on related copper peptides, plus a few claims that change meaning once you read the source. Each finding below is labeled by study type:

• 🧪 Lab / ex vivo: cells or hair follicles kept alive in culture
• 🐭 Animal: mice and rats
• 👤 Human: topical cosmetic studies

Research-grade GHK-Cu is meant only for laboratory work, as our Medical Disclaimer spells out.

What Is GHK-Cu? A Quick Recap

GHK-Cu is a copper-binding peptide made of glycine, histidine and lysine, found naturally in human plasma. It’s best known from skin research on collagen and wound repair, and it appears in cosmetic scalp and hair products as well as in research-grade form. Its hair story grows out of its skin research. Hair follicles are rooted in the dermis, surrounded by the same fibroblasts and blood vessels GHK-Cu has been studied on, so researchers asked whether its effects there might extend to follicles. Our GHK-Cu guide covers the molecule, and our GHK-Cu benefits page reviews its other research areas.

How GHK-Cu Is Thought to Act on Hair Follicles: Lab Research

Lab research suggests copper tripeptides may encourage multiplication of dermal papilla cells, which steer follicle growth, and reduce their programmed cell death. The key human-follicle study, though, tested AHK-Cu, a close relative of GHK-Cu.

Dermal Papilla Cell Studies

🧪 Dermal papilla cells are found at the base of each follicle and send the signals that control its growth cycle. In a 2007 study by Pyo and colleagues at Seoul National University, a copper tripeptide increased the growth of cultured human dermal papilla cells. It also moved markers of programmed cell death in a protective direction, raising the Bcl-2/Bax ratio and lowering cleaved caspase-3. The peptide was AHK-Cu, which swaps GHK’s glycine for alanine. The authors’ introduction notes that copper tripeptides raise production of VEGF, a blood-vessel growth factor, by skin fibroblasts, while lowering TGF-β1, a signal associated with the end of the growth phase. Those two changes are why researchers see a plausible route from copper peptides to follicle activity. The study worked at extremely low concentrations, in the picomolar to nanomolar range, which tells us the effect occurred in a dish at tiny amounts and says nothing about any product concentration.

Ex Vivo Follicle Culture

🧪 In the same study, cultured human hair follicles grew longer with AHK-Cu at very low concentrations. Ex vivo models are valuable because they use real human follicles. They also have clear limits: the follicle is cut off from its blood supply, immune system and hormones, and it survives only days to weeks, so it can’t show whether visible hair changes would follow in living skin. It helps to know what researchers are measuring. Each follicle cycles through a growth phase (anagen), a short transition (catagen) and a resting phase (telogen). Longer anagen means longer hair, and in pattern hair loss, anagen shortens and follicles shrink over successive cycles. An ex vivo culture captures part of one anagen phase, which is why follicle length is its main readout. It can’t capture repeated cycles, follicle shrinkage or the hormonal signals that drive pattern hair loss.

Proposed Pathways: Wnt, Angiogenesis, 5-Alpha-Reductase

Three mechanisms circulate online, and their support varies:

• Angiogenesis. 🧪 Copper peptides raise VEGF in fibroblasts, a reasonably documented link, as Pyo and colleagues summarize.
• Wnt/β-catenin signaling. 🐭 A 2024 mouse delivery study by Liu and colleagues reported increased Wnt/β-catenin activity, a pathway that regulates follicle cycling, with its GHK-Cu formulation.
• 5-alpha-reductase. We couldn’t find a primary study showing GHK-Cu inhibits this enzyme. The claim appears on product pages without a source.

GHK-Cu Hair Research at a Glance: Study Table

Published hair research on copper peptides consists of about six studies: two older animal reports, one ex vivo human follicle study of AHK-Cu, one mouse delivery study of GHK-Cu, one human combination study and one small 2026 eyebrow study. Only two tested GHK-Cu specifically.

Durations here describe study designs only. [image]

Animal Studies

Animal research on copper peptides and hair includes a 1991 mouse report co-authored by Loren Pickart, a 1993 study of a copper-binding peptide in rats and a 2024 mouse study of a GHK-Cu delivery system. Results pointed toward follicle stimulation, though the peptides and methods differ. 🐭 1991, mice. Trachy, Pickart, Uno and colleagues reported on the hair follicle-stimulating properties of peptide copper complexes in C3H mice, in a short conference paper whose indexed record has no abstract. We couldn’t confirm the specific “follicle size near wounds” detail some summaries attribute to Pickart’s early work. 🐭 1993, rats. At the Wisconsin primate research center, Uno and Kurata found that a copper-binding peptide called PC1031 made back-skin follicles grow larger in fuzzy rats. 🐭 2024, mice. Liu and colleagues built an ionic-liquid microemulsion that improved GHK-Cu delivery into skin about three-fold and tested it in mice, reporting more VEGF and Wnt activity. The authors describe copper peptides as “a powerful hair growth promoter with minimal side effects when compared with minoxidil and finasteride,” a view their delivery data support in mice, with human testing still ahead.

Human Studies: What’s Actually Been Published

Human hair data on GHK-Cu are minimal: a small 2026 eyebrow study reported positive cosmetic outcomes, and a 2025 study tested copper peptides only in combination with two hair-loss drugs. The widely repeated 1993 “comparable to minoxidil” human trial turns out to be a rat study.

The 1993 “Comparable to Minoxidil” Claim

Several hair pages state that a 1993 trial found GHK-Cu comparable to 5% minoxidil. We traced the claim to Uno and Kurata’s 1993 paper in the Journal of Investigative Dermatology. That paper describes a copper-binding peptide, PC1031, enlarging follicles in fuzzy rats, with an effect the authors called “similar to that of topical minoxidil.” Three details change the meaning:

• It was a rat study, with no human participants.
• The peptide was PC1031, which the paper doesn’t identify as GHK-Cu.
• The comparison was to topical minoxidil in the same rat model, with no concentration given in the abstract.

The finding is real and interesting for animal research. It doesn’t show anything about GHK-Cu and human hair.

The 2026 Eyebrow Study

👤 The August 2026 Pharmaceutics review by Mateescu and colleagues describes a 2026 eyebrow study of 18 participants, comparing one side of the face with the other, that “reported positive cosmetic hair outcomes.” It’s the most direct human data on GHK-Cu and hair so far. The reviewers note it didn’t define the GHK-Cu’s chemical form or how much reached the skin, and we couldn’t locate the primary paper in PubMed to check its design further.

GHK-Cu and Hair Loss Research: Who Has Been Studied

👤 The only human hair loss research involving copper peptides is a 2025 study in JAAD International by Kuceki and colleagues. Adults with androgenetic alopecia, the common pattern form of hair loss, received five monthly sessions of a mixture delivered into the scalp: minoxidil, dutasteride and copper peptides together. Hair regrowth was assessed by artificial intelligence and blinded evaluators. Because the copper peptides were one of three active ingredients, the study can’t show what they contributed on their own. Androgenetic alopecia is the research population that draws the most commercial interest, and it’s driven by sensitivity to dihydrotestosterone (DHT), a hormone made from testosterone by the enzyme 5-alpha-reductase. That’s why the unsupported 5-alpha-reductase claim above draws attention, and why a copper peptide study in this population would need a peptide-only group to say anything about GHK-Cu. No published study has examined GHK-Cu alone in people with hair loss.

GHK-Cu vs AHK-Cu: Two Different Copper Peptides

GHK-Cu and AHK-Cu are both copper-binding tripeptides, differing in one amino acid: glycine in GHK, alanine in AHK. Their research records are separate, and the main human follicle study tested AHK-Cu. Evidence for one shouldn’t be credited to the other. A single amino acid can change how tightly a peptide holds copper, how it’s broken down and which cell receptors it meets. That makes the GHK-Cu and AHK-Cu question a chemistry issue as much as a labeling one.

Some hair serums combine more than one copper peptide, which is one reason “copper peptide hair” evidence gets pooled online.

Topical vs Injectable: No Hair Data for Injectable GHK-Cu

No published study has examined injectable GHK-Cu for hair, in animals or people. Every hair study involving GHK-Cu used topical application or cultured tissue, so hair claims for injectable research peptides have no direct evidence behind them. That distinction counts because route changes almost everything about a peptide: how much reaches the follicle, how long it lasts and what else it touches along the way. The FDA characterizes human data on injectable GHK-Cu as limited, whatever the purpose. A full injectable-versus-topical comparison is planned for a future KlowStack guide.

GHK-Cu in Hair Research Alongside Other Peptides

GHK-Cu makes up 50 mg of both the KLOW and GLOW research blends. Neither blend has been studied for hair. TB-500’s parent protein, thymosin beta-4, has separate hair data in rats and mice. Our upcoming GLOW skin and hair guide compares the components, and our KLOW for skin research page covers the four-peptide blend.

Limits of the Research

The main limits are that few studies exist, most are animal or lab work, the human studies are tiny or combine copper peptides with drugs, and GHK-Cu evidence is often mixed up with evidence for AHK-Cu or other copper peptides.

• Very few studies, with about six in total across all models
• Small samples, such as 18 people in the eyebrow study
• Mixed peptides, including AHK-Cu and PC1031 standing in for GHK-Cu
• Combination designs, where copper peptides’ effect can’t be isolated
• Industry ties, since early copper peptide research involved the compound’s developers
• Undefined chemistry, with the 2026 review noting that bound versus free copper usually goes unmeasured

The Pharmaceutics reviewers describe the next step constructively, calling GHK-Cu “a promising but unproven therapeutic cargo” until its chemistry is better controlled and controlled clinical evidence arrives. For hair, that means a placebo-controlled trial of GHK-Cu alone, with a defined formulation, would move the field more than any number of product claims. For side effects reported in GHK-Cu research, see our upcoming GHK-Cu side effects guide. A plain-English guide to reading peptide studies is also on the way.

FAQ

What has hair research found about GHK-Cu?

A 2024 mouse study found more hair growth markers with a GHK-Cu delivery system, and a small 2026 eyebrow study reported positive cosmetic outcomes. Most other hair studies used related copper peptides such as AHK-Cu.

Is GHK-Cu FDA-approved for hair loss?

No. GHK-Cu isn’t FDA-approved for hair loss or any other medical use. In hair products it’s used as a cosmetic ingredient.

What is the difference between GHK-Cu and AHK-Cu?

They’re copper-binding tripeptides that differ by one amino acid, glycine versus alanine. GHK-Cu occurs naturally in plasma, while AHK-Cu is synthetic and is the peptide in the main human follicle study.

Has injectable GHK-Cu been studied for hair?

No. Every hair study involving GHK-Cu used topical application or cultured tissue.

What side effects have GHK-Cu studies reported?

Small topical studies didn’t systematically record side effects, and no human safety data exist for systemic forms. Our upcoming GHK-Cu side effects guide covers the findings by route.

Conclusion

GHK-Cu’s hair research is early and narrow. Its most quoted human “trial” was a rat study, its best follicle data belong to AHK-Cu, and its own human hair evidence is one small eyebrow study.